Tempest Therapeutics Overview
Latest ROE for Tempest Therapeutics: 3713.03% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow3713.03%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, TPST shows a ROE of 3713.03%. That is above the Healthcare sector average of 21.67%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.67%. Tempest Therapeutics is at 3713.03%, which is higher that average. That is roughly 17035.9% above the sector mean. Use the comparison chart on this page to see how TPST stacks up against individual peers as well.
Check the historical chart to see whether TPST's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Tempest Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Tempest Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 3713.03%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.67%, while TPST is at 3713.03%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
